Dual anticancer drug/superparamagnetic iron oxide-loaded PLGA-based nanoparticles for cancer therapy and magnetic resonance imaging
(2013) International Journal of Pharmaceutics — Vol. 447, n° 1-2, p. 94-101 (2013)
Files
Schleich2013.pdf
Open Access - Adobe PDF
- 865.12 KB
Details
- Authors
Danhier, Pierre 
- Abstract
- We developed dual paclitaxel (PTX)/superparamagnetic iron oxide (SPIO)-loaded PLGA-based nanoparticles for a theranostic purpose. Nanoparticles presented a spherical morphology and a size of 240 nm. The PTX and iron loading were 1.84 ± 0.4 and 10.4 ± 1.93 mg/100 mg respectively. Relaxometry studies and phantom MRI demonstrated their efficacy as T₂ contrast agent. Significant cellular uptake by CT26 cells of nanoparticles was shown by Prussian blue staining and fluorescent microscopy. While SPIO did not show any toxicity in CT-26 cells, PTX-loaded nanoparticles had a cytotoxic activity. PTX-loaded nanoparticle (5 mg/kg) with or without co-encapulated SPIO induced in vivo a regrowth delay of CT26 tumors. Together these multifunctional nanoparticles may be considered as future nanomedicine for simultaneous molecular imaging, drug delivery and real-time monitoring of therapeutic response
- Affiliations
Citations
Schleich, N., Sibret, P., Danhier, P., Ucakar, B., Laurent, S., Muller, R. N., Jérôme, C., Gallez, B., Préat, V., & Danhier, F. (2013). Dual anticancer drug/superparamagnetic iron oxide-loaded PLGA-based nanoparticles for cancer therapy and magnetic resonance imaging. International Journal of Pharmaceutics, 447(1-2), 94-101. https://doi.org/10.1016/j.ijpharm.2013.02.042 (Original work published 2013)